{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:51:25Z","timestamp":1791575485578,"version":"4.3.4"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["LU1571\/18-1"],"award-info":[{"award-number":["LU1571\/18-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["PO1458\/5-2"],"award-info":[{"award-number":["PO1458\/5-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["JU426\/6-1"],"award-info":[{"award-number":["JU426\/6-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["decision 342983"],"award-info":[{"award-number":["decision 342983"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70112693"],"award-info":[{"award-number":["70112693"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009379","name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung, Universit\u00e4tsklinikum W\u00fcrzburg","doi-asserted-by":"publisher","award":["B-263"],"award-info":[{"award-number":["B-263"]}],"id":[{"id":"10.13039\/501100009379","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Drug resistance causes tumor relapse, limits the outcomes of patients with high-risk multiple myeloma (MM), and requires the development of targeted therapeutics. Increased Notch signaling promotes drug resistance in high-risk del(17p)\/TP53-deficient clonogenic MM cells, highlighting the pathway and its downstream effectors as rational therapeutic targets in aggressive MM. However, the identification of selective, safe, and efficacious inhibitors targeting the Notch pathway remains a substantial challenge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      To identify novel druggable Notch effectors, we performed transcriptome profiling of Notch-depleted MM cells and selected potential candidates. We applied functional high-throughput shRNA library screens targeting these genes in MM cells with high Notch activity and under drug selection. Through bioinformatic analysis, we selected NFIL3 and validated its mechanistic specificity using ChIP-seq analysis, immunoblotting, cell viability and growth assays. We targeted NFIL3 via the oleanane-type triterpenoid saponin Raddeanin A (RA) and tested its efficacy in vivo using the murine MOPC.315.BM.Luc.eGFP-\n                      <jats:italic>mCrbn<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>I391V<\/jats:italic>\n                      <\/jats:sup>\n                      model. To improve efficacy of RA in vivo, we developed drug-loaded nanocarriers based on polymer micelles. Using patient MM cells with high-risk cytogenetic abnormalities and post B-cell maturation antigen (BCMA)-directed immunotherapy, we demonstrated efficacy of RA to circumvent multi-drug resistance. To determine the prognostic significance of NFIL3, we correlated its transcriptional expression with survival data and cytogenetic abnormalities of two patient cohorts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In functional genomics screens, we identified NFIL3 as a critical therapeutic vulnerability in high-risk, multidrug-resistant MM. Mechanistic studies silencing NFIL3 revealed that NFIL3 acts as a repressor of the MYC oncogenic driver in MM cells. RA collapsed the MYC-driven transcriptional program essential for MM cell survival and abrogated multidrug resistance of human and murine MM cells in vitro and in vivo. Importantly, the drug RA demonstrated potent anti-myeloma activity in patient-derived cells with high-risk cytogenetics following failure of BCMA-directed immunotherapies. Furthermore, high\n                      <jats:italic>NFIL3<\/jats:italic>\n                      expression was associated with high-risk cytogenetic abnormalities and extramedullary disease and was verified as an independent prognostic marker for overall survival in MM patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RA targets the NFIL3-MYC axis and demonstrates potent anti-myeloma activity in vivo and in patient-derived high-risk MM cells following failure of BCMA-directed immunotherapies, providing a potent salvage strategy for multi-refractory disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40364-026-01018-7","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:41:10Z","timestamp":1791528070000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The NFIL3-MYC signaling axis: a novel therapeutic target and prognostic marker in high-risk multiple myeloma"],"prefix":"10.1186","volume":"14","author":[{"given":"Daniela Simone","family":"Maichl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hui","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius Arthur","family":"Kirner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten Patrick","family":"Ade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengshi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik Salman","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuquan","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Luxenhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyudmyla","family":"Taranets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Haffner-Luntzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Ignatius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Leich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Zapata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Popov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8661-7110","authenticated-orcid":false,"given":"Franziska","family":"Jundt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"issue":"8","key":"1018_CR1","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/ajh.27327","volume":"99","author":"MJ Rees","year":"2024","unstructured":"Rees MJ, Kumar S. High-risk multiple myeloma: Redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy. Am J Hematol. 2024;99(8):1560\u201375.","journal-title":"Am J Hematol"},{"issue":"24","key":"1018_CR2","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO-24-01893","volume":"43","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau H, Davies FE, Samur MK, Corre J, D\u2019Agostino M, Kaiser MF, et al. International Myeloma Society\/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. J Clin Oncol. 2025;43(24):2739\u201351.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1018_CR3","first-page":"3065","volume":"110","author":"AJ Portuguese","year":"2025","unstructured":"Portuguese AJ, Liang EC, Huang JJ, Jeon Y, Dima D, Banerjee R, et al. Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma. Haematologica. 2025;110(12):3065\u201377.","journal-title":"Haematologica"},{"issue":"23","key":"1018_CR4","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood.2023023616","volume":"144","author":"C Touzeau","year":"2024","unstructured":"Touzeau C, Krishnan AY, Moreau P, Perrot A, Usmani SZ, Manier S, et al. Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies. Blood. 2024;144(23):2375\u201388.","journal-title":"Blood"},{"issue":"14","key":"1018_CR5","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1182\/bloodadvances.2022009387","volume":"7","author":"YT Chang","year":"2023","unstructured":"Chang YT, Chiu I, Wang Q, Bustamante J, Jiang W, Rycaj K, et al. Loss of p53 enhances the tumor-initiating potential and drug resistance of clonogenic multiple myeloma cells. Blood Adv. 2023;7(14):3551\u201360.","journal-title":"Blood Adv"},{"issue":"7","key":"1018_CR6","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.3324\/haematol.2019.221077","volume":"105","author":"M Colombo","year":"2020","unstructured":"Colombo M, Garavelli S, Mazzola M, Platonova N, Giannandrea D, Colella R, et al. Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance. Haematologica. 2020;105(7):1925\u201336.","journal-title":"Haematologica"},{"issue":"9","key":"1018_CR7","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1182\/blood-2003-07-2254","volume":"103","author":"F Jundt","year":"2004","unstructured":"Jundt F, Probsting KS, Anagnostopoulos I, Muehlinghaus G, Chatterjee M, Mathas S, et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood. 2004;103(9):3511\u20135.","journal-title":"Blood"},{"issue":"1","key":"1018_CR8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41408-023-00907-6","volume":"13","author":"DS Maichl","year":"2023","unstructured":"Maichl DS, Kirner JA, Beck S, Cheng WH, Krug M, Kuric M, et al. Identification of NOTCH-driven matrisome-associated genes as prognostic indicators of multiple myeloma patient survival. Blood Cancer J. 2023;13(1):134.","journal-title":"Blood Cancer J"},{"issue":"12","key":"1018_CR9","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41408-017-0001-3","volume":"7","author":"Y Muguruma","year":"2017","unstructured":"Muguruma Y, Yahata T, Warita T, Hozumi K, Nakamura Y, Suzuki R, et al. Jagged1-induced Notch activation contributes to the acquisition of bortezomib resistance in myeloma cells. Blood Cancer J. 2017;7(12):650.","journal-title":"Blood Cancer J"},{"issue":"9","key":"1018_CR10","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1182\/blood-2003-07-2340","volume":"103","author":"Y Nefedova","year":"2004","unstructured":"Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood. 2004;103(9):3503\u201310.","journal-title":"Blood"},{"issue":"4","key":"1018_CR11","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1182\/blood-2007-07-102632","volume":"111","author":"Y Nefedova","year":"2008","unstructured":"Nefedova Y, Sullivan DM, Bolick SC, Dalton WS, Gabrilovich DI. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood. 2008;111(4):2220\u20139.","journal-title":"Blood"},{"issue":"19","key":"1018_CR12","doi-asserted-by":"publisher","first-page":"5102","DOI":"10.1158\/0008-5472.CAN-21-0524","volume":"81","author":"HM Sabol","year":"2021","unstructured":"Sabol HM, Ferrari AJ, Adhikari M, Amorim T, McAndrews K, Anderson J, et al. Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity. Cancer Res. 2021;81(19):5102\u201314.","journal-title":"Cancer Res"},{"issue":"4","key":"1018_CR13","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.bbrc.2012.10.071","volume":"428","author":"D Xu","year":"2012","unstructured":"Xu D, Hu J, De Bruyne E, Menu E, Schots R, Vanderkerken K, et al. Dll1\/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma. Biochem Biophys Res Commun. 2012;428(4):518\u201324.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"1018_CR14","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1182\/blood-2003-07-2254","volume":"103","author":"F Jundt","year":"2004","unstructured":"Jundt F, Pr\u00f6bsting KS, Anagnostopoulos I, Muehlinghaus G, Chatterjee M, Mathas S, et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood. 2004;103(9):3511\u20135.","journal-title":"Blood"},{"issue":"35","key":"1018_CR15","doi-asserted-by":"publisher","first-page":"56013","DOI":"10.18632\/oncotarget.10820","volume":"7","author":"M Colombo","year":"2016","unstructured":"Colombo M, Galletti S, Bulfamante G, Falleni M, Tosi D, Todoerti K, et al. Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche. Oncotarget. 2016;7(35):56013\u201329.","journal-title":"Oncotarget"},{"key":"1018_CR16","doi-asserted-by":"crossref","unstructured":"Sabol HM, Ashby C, Adhikari M, Anloague A, Kaur J, Khan S et al. A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma. Haematologica. 2024;109(8):2606\u20132618.","DOI":"10.3324\/haematol.2023.284443"},{"issue":"19","key":"1018_CR17","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1200\/JCO.2011.39.1540","volume":"30","author":"I Krop","year":"2012","unstructured":"Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol. 2012;30(19):2307\u201313.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1018_CR18","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1093\/annonc\/mdy171","volume":"29","author":"R Ferrarotto","year":"2018","unstructured":"Ferrarotto R, Eckhardt G, Patnaik A, LoRusso P, Faoro L, Heymach JV, et al. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol. 2018;29(7):1561\u20138.","journal-title":"Ann Oncol"},{"key":"1018_CR19","doi-asserted-by":"crossref","unstructured":"Cowan AJ, Pont MJ, Sather BD, Turtle CJ, Till BG, Libby EN 3, et al. gamma-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Lancet Oncol. 2023;24(7):811\u201322.","DOI":"10.1016\/S1470-2045(23)00246-2"},{"issue":"19","key":"1018_CR20","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","volume":"134","author":"MJ Pont","year":"2019","unstructured":"Pont MJ, Hill T, Cole GO, Abbott JJ, Kelliher J, Salter AI, et al. gamma-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019;134(19):1585\u201397.","journal-title":"Blood"},{"issue":"5","key":"1018_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules25051035","volume":"25","author":"I Naz","year":"2020","unstructured":"Naz I, Ramchandani S, Khan MR, Yang MH, Ahn KS. Anticancer Potential of Raddeanin A, a Natural Triterpenoid Isolated from Anemone raddeana Regel. Molecules. 2020;25(5):1\u201320.","journal-title":"Molecules"},{"issue":"1","key":"1018_CR22","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41408-024-01133-4","volume":"14","author":"M Evers","year":"2024","unstructured":"Evers M, Stuhmer T, Schreder M, Steinbrunn T, Rudelius M, Jundt F, et al. Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma. Blood Cancer J. 2024;14(1):156.","journal-title":"Blood Cancer J"},{"key":"1018_CR23","doi-asserted-by":"crossref","unstructured":"Settino M, Cannataro M. MMRFBiolinks: an R-package for integrating and analyzing MMRF-CoMMpass data. Brief Bioinform. 2021;22(5):1-12.","DOI":"10.1093\/bib\/bbab050"},{"issue":"4","key":"1018_CR24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14(4):417\u20139.","journal-title":"Nat Methods"},{"issue":"43","key":"1018_CR25","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1018_CR26","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.celrep.2013.11.020","volume":"5","author":"C Fellmann","year":"2013","unstructured":"Fellmann C, Hoffmann T, Sridhar V, Hopfgartner B, Muhar M, Roth M, et al. An optimized microRNA backbone for effective single-copy RNAi. Cell Rep. 2013;5(6):1704\u201313.","journal-title":"Cell Rep"},{"issue":"1","key":"1018_CR27","doi-asserted-by":"publisher","first-page":"101183","DOI":"10.1016\/j.xpro.2022.101183","volume":"3","author":"D Papadopoulos","year":"2022","unstructured":"Papadopoulos D, Ade CP, Eilers M. Generation of a pooled shRNA library for functional genomics screens. STAR Protoc. 2022;3(1):101183.","journal-title":"STAR Protoc"},{"issue":"14","key":"1018_CR28","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/onc.2016.354","volume":"36","author":"LA Jung","year":"2017","unstructured":"Jung LA, Gebhardt A, Koelmel W, Ade CP, Walz S, Kuper J, et al. OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors. Oncogene. 2017;36(14):1911\u201324.","journal-title":"Oncogene"},{"issue":"9","key":"1018_CR29","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1182\/blood.V99.9.3398","volume":"99","author":"F Jundt","year":"2002","unstructured":"Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood. 2002;99(9):3398\u2013403.","journal-title":"Blood"},{"key":"1018_CR30","doi-asserted-by":"publisher","first-page":"5150634","DOI":"10.1155\/2019\/5150634","volume":"2019","author":"F Ziouti","year":"2019","unstructured":"Ziouti F, Ebert R, Rummler M, Krug M, Muller-Deubert S, Ludemann M, et al. NOTCH Signaling Is Activated through Mechanical Strain in Human Bone Marrow-Derived Mesenchymal Stromal Cells. Stem Cells Int. 2019;2019:5150634.","journal-title":"Stem Cells Int"},{"issue":"9","key":"1018_CR31","first-page":"3398","volume":"99","author":"F Jundt","year":"2002","unstructured":"Jundt F, Anagnostopoulos I, F\u00f6rster R, Mathas S, Stein H, D\u00f6rken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood J Am Soc Hematol. 2002;99(9):3398\u2013403.","journal-title":"Blood J Am Soc Hematol"},{"key":"1018_CR32","doi-asserted-by":"publisher","first-page":"115624","DOI":"10.1016\/j.bone.2020.115624","volume":"141","author":"H Hariri","year":"2020","unstructured":"Hariri H, Pellicelli M, St-Arnaud R. Nfil3, a target of the NACA transcriptional coregulator, affects osteoblast and osteocyte gene expression differentially. Bone. 2020;141:115624.","journal-title":"Bone"},{"key":"1018_CR33","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1038\/bcj.2014.37","volume":"4","author":"R Schwarzer","year":"2014","unstructured":"Schwarzer R, Nickel N, Godau J, Willie BM, Duda GN, Schwarzer R, et al. Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model. Blood Cancer J. 2014;4:e217.","journal-title":"Blood Cancer J"},{"issue":"7","key":"1018_CR34","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/jbmr.141","volume":"25","author":"ML Bouxsein","year":"2010","unstructured":"Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Min Res. 2010;25(7):1468\u201386.","journal-title":"J Bone Min Res"},{"issue":"6","key":"1018_CR35","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1021\/acs.molpharmaceut.9b01117","volume":"17","author":"MM Lubtow","year":"2020","unstructured":"Lubtow MM, Oerter S, Quader S, Jeanclos E, Cubukova A, Krafft M, et al. In Vitro Blood-Brain Barrier Permeability and Cytotoxicity of an Atorvastatin-Loaded Nanoformulation Against Glioblastoma in 2D and 3D Models. Mol Pharm. 2020;17(6):1835\u201347.","journal-title":"Mol Pharm"},{"key":"1018_CR36","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jconrel.2019.04.014","volume":"303","author":"MM Lubtow","year":"2019","unstructured":"Lubtow MM, Nelke LC, Seifert J, Kuhnemundt J, Sahay G, Dandekar G, et al. Drug induced micellization into ultra-high capacity and stable curcumin nanoformulations: Physico-chemical characterization and evaluation in 2D and 3D in vitro models. J Control Release. 2019;303:162\u201380.","journal-title":"J Control Release"},{"issue":"3","key":"1018_CR37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41408-021-00442-2","volume":"11","author":"E Leich","year":"2021","unstructured":"Leich E, Schreder M, Pischimarov J, Stuhmer T, Steinbrunn T, Rudelius M, et al. Novel molecular subgroups within the context of receptor tyrosine kinase and adhesion signalling in multiple myeloma. Blood Cancer J. 2021;11(3):51.","journal-title":"Blood Cancer J"},{"issue":"2","key":"1018_CR38","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/sj.bjc.6601118","volume":"89","author":"TG Clark","year":"2003","unstructured":"Clark TG, Bradburn MJ, Love SB, Altman DG. Survival analysis part I: basic concepts and first analyses. Br J Cancer. 2003;89(2):232\u20138.","journal-title":"Br J Cancer"},{"key":"1018_CR39","doi-asserted-by":"crossref","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple hypothesis testing. J R Stat Soc B. 1995;57(1):289-300.","DOI":"10.1111\/j.2517-6161.1995.tb02031.x"},{"issue":"6","key":"1018_CR40","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1038\/bcj.2014.37","volume":"4","author":"R Schwarzer","year":"2014","unstructured":"Schwarzer R, Nickel N, Godau J, Willie B, Duda G, Cirovic B, et al. Notch pathway inhibition controls myeloma bone disease in the murine MOPC315. BM model. Blood cancer J. 2014;4(6):e217\u2013e.","journal-title":"Blood cancer J"},{"key":"1018_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.semcdb.2020.05.019","volume":"105","author":"G Guner","year":"2020","unstructured":"Guner G, Lichtenthaler SF. The substrate repertoire of gamma-secretase\/presenilin. Semin Cell Dev Biol. 2020;105:27\u201342.","journal-title":"Semin Cell Dev Biol"},{"issue":"7201","key":"1018_CR42","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature07064","volume":"454","author":"AL Shaffer","year":"2008","unstructured":"Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, et al. IRF4 addiction in multiple myeloma. Nature. 2008;454(7201):226\u201331.","journal-title":"Nature"},{"issue":"1","key":"1018_CR43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","volume":"149","author":"CV Dang","year":"2012","unstructured":"Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22\u201335.","journal-title":"Cell"},{"issue":"2","key":"1018_CR44","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/leu.2011.192","volume":"26","author":"V Ramakrishnan","year":"2012","unstructured":"Ramakrishnan V, Ansell S, Haug J, Grote D, Kimlinger T, Stenson M, et al. MRK003, a gamma-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin\u2019s lymphoma. Leukemia. 2012;26(2):340\u20138.","journal-title":"Leukemia"},{"issue":"4","key":"1018_CR45","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1161\/ATVBAHA.117.310388","volume":"38","author":"LC Poulsen","year":"2018","unstructured":"Poulsen LC, Edelmann RJ, Kruger S, Dieguez-Hurtado R, Shah A, Stav-Noraas TE, et al. Inhibition of Endothelial NOTCH1 Signaling Attenuates Inflammation by Reducing Cytokine-Mediated Histone Acetylation at Inflammatory Enhancers. Arterioscler Thromb Vasc Biol. 2018;38(4):854\u201369.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"1018_CR46","doi-asserted-by":"publisher","first-page":"5370","DOI":"10.1002\/jcp.26362","volume":"233","author":"Z Peng","year":"2018","unstructured":"Peng Z, Zhang C, Zhou W, Wu C, Zhang Y. The STAT3\/NFIL3 signaling axis-mediated chemotherapy resistance is reversed by Raddeanin A via inducing apoptosis in choriocarcinoma cells. J Cell Physiol. 2018;233(7):5370\u201382.","journal-title":"J Cell Physiol"},{"issue":"6","key":"1018_CR47","doi-asserted-by":"publisher","first-page":"e2001382","DOI":"10.1002\/adhm.202001382","volume":"10","author":"A Zahoranova","year":"2021","unstructured":"Zahoranova A, Luxenhofer R. Poly(2-oxazoline)- and Poly(2-oxazine)-Based Self-Assemblies, Polyplexes, and Drug Nanoformulations-An Update. Adv Healthc Mater. 2021;10(6):e2001382.","journal-title":"Adv Healthc Mater"},{"issue":"1","key":"1018_CR48","doi-asserted-by":"publisher","first-page":"e1900178","DOI":"10.1002\/mabi.201900178","volume":"20","author":"MS Haider","year":"2020","unstructured":"Haider MS, Schreiner J, Kendl S, Kroiss M, Luxenhofer R. A Micellar Mitotane Formulation with High Drug-Loading and Solubility: Physico-Chemical Characterization and Cytotoxicity Studies in 2D and 3D In Vitro Tumor Models. Macromol Biosci. 2020;20(1):e1900178.","journal-title":"Macromol Biosci"},{"issue":"12","key":"1018_CR49","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1182\/blood-2011-08-371567","volume":"120","author":"T Holien","year":"2012","unstructured":"Holien T, Vatsveen TK, Hella H, Waage A, Sundan A. Addiction to c-MYC in multiple myeloma. Blood. 2012;120(12):2450\u20133.","journal-title":"Blood"},{"issue":"1","key":"1018_CR50","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11033-023-09079-9","volume":"51","author":"L Wang","year":"2024","unstructured":"Wang L, Li P, Zhang X, Gu Z, Pan X, Wu Y, et al. The role of basic leucine zipper transcription factor E4BP4 in cancer: a review and update. Mol Biol Rep. 2024;51(1):91.","journal-title":"Mol Biol Rep"},{"issue":"11","key":"1018_CR51","doi-asserted-by":"publisher","first-page":"6055","DOI":"10.1128\/MCB.15.11.6055","volume":"15","author":"W Zhang","year":"1995","unstructured":"Zhang W, Zhang J, Kornuc M, Kwan K, Frank R, Nimer SD. Molecular cloning and characterization of NF-IL3A, a transcriptional activator of the human interleukin-3 promoter. Mol Cell Biol. 1995;15(11):6055\u201363.","journal-title":"Mol Cell Biol"},{"issue":"8","key":"1018_CR52","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1248\/cpb.c14-00138","volume":"62","author":"S Qian","year":"2014","unstructured":"Qian S, Chen QL, Guan JL, Wu Y, Wang ZY. Synthesis and biological evaluation of Raddeanin A, a triterpene saponin isolated from Anemone raddeana. Chem Pharm Bull (Tokyo). 2014;62(8):779\u201385.","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"1018_CR53","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.lfs.2018.06.035","volume":"207","author":"Y Wang","year":"2018","unstructured":"Wang Y, Bao X, Zhao A, Zhang J, Zhang M, Zhang Q, et al. Raddeanin A inhibits growth and induces apoptosis in human colorectal cancer through downregulating the Wnt\/beta-catenin and NF-kappaB signaling pathway. Life Sci. 2018;207:532\u201349.","journal-title":"Life Sci"},{"issue":"1","key":"1018_CR54","doi-asserted-by":"publisher","first-page":"29061","DOI":"10.1038\/s41598-024-76465-z","volume":"14","author":"MZ Jiang","year":"2024","unstructured":"Jiang MZ, Li C, Mao CM, Yu H, Zhou YC, Pu SQ, et al. The MAPK\/ERK signaling pathway involved in Raddeanin A induces apoptosis via the mitochondrial pathway and G2 phase arrest in multiple myeloma. Sci Rep. 2024;14(1):29061.","journal-title":"Sci Rep"},{"issue":"1","key":"1018_CR55","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41588-020-00752-4","volume":"53","author":"C Valero","year":"2021","unstructured":"Valero C, Lee M, Hoen D, Wang J, Nadeem Z, Patel N, et al. The association between tumor mutational burden and prognosis is dependent on treatment context. Nat Genet. 2021;53(1):11\u20135.","journal-title":"Nat Genet"},{"issue":"8","key":"1018_CR56","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1101\/gad.214049.113","volume":"27","author":"M Keniry","year":"2013","unstructured":"Keniry M, Pires MM, Mense S, Lefebvre C, Gan B, Justiano K, et al. Survival factor NFIL3 restricts FOXO-induced gene expression in cancer. Genes Dev. 2013;27(8):916\u201327.","journal-title":"Genes Dev"},{"issue":"6168","key":"1018_CR57","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kronke","year":"2014","unstructured":"Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343(6168):301\u20135.","journal-title":"Science"},{"issue":"12","key":"1018_CR58","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr., Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107(12):4907\u201316.","journal-title":"Blood"},{"issue":"1","key":"1018_CR59","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/blood.V100.1.224","volume":"100","author":"VJ Spanswick","year":"2002","unstructured":"Spanswick VJ, Craddock C, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG, et al. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood. 2002;100(1):224\u20139.","journal-title":"Blood"},{"issue":"1","key":"1018_CR60","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1158\/2643-3230.BCD-23-0061","volume":"5","author":"P Neri","year":"2024","unstructured":"Neri P, Barwick BG, Jung D, Patton JC, Maity R, Tagoug I, et al. ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma. Blood Cancer Discov. 2024;5(1):56\u201373.","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"1018_CR61","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41419-018-0417-0","volume":"9","author":"Q Wang","year":"2018","unstructured":"Wang Q, Mo J, Zhao C, Huang K, Feng M, He W, et al. Raddeanin A suppresses breast cancer-associated osteolysis through inhibiting osteoclasts and breast cancer cells. Cell Death Dis. 2018;9(3):376.","journal-title":"Cell Death Dis"},{"issue":"32","key":"1018_CR62","doi-asserted-by":"publisher","first-page":"10980","DOI":"10.1021\/jacs.7b05376","volume":"139","author":"MM L\u00fcbtow","year":"2017","unstructured":"L\u00fcbtow MM, Hahn L, Haider MS, Luxenhofer R. Drug specificity, synergy and antagonism in ultrahigh capacity poly(2-oxazoline)\/poly(2-oxazine) based formulations. J Am Chem Soc. 2017;139(32):10980\u20133.","journal-title":"J Am Chem Soc"},{"key":"1018_CR63","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.biomaterials.2016.06.002","volume":"101","author":"Z He","year":"2016","unstructured":"He Z, Wan X, Schulz A, Bludau H, Dobrovolskaia MA, Stern ST, et al. A high capacity polymeric micelle of paclitaxel: Implication of high dose drug therapy to safety and in vivo anti-cancer activity. Biomaterials. 2016;101:296\u2013309.","journal-title":"Biomaterials"},{"key":"1018_CR64","doi-asserted-by":"publisher","first-page":"121140","DOI":"10.1016\/j.biomaterials.2021.121140","volume":"278","author":"D Hwang","year":"2021","unstructured":"Hwang D, Vinod N, Skoczen SL, Ramsey JD, Snapp KS, Montgomery SA, et al. Bioequivalence assessment of high-capacity polymeric micelle nanoformulation of paclitaxel and Abraxane(R) in rodent and non-human primate models using a stable isotope tracer assay. Biomaterials. 2021;278:121140.","journal-title":"Biomaterials"},{"key":"1018_CR65","doi-asserted-by":"publisher","first-page":"102345","DOI":"10.1016\/j.nano.2020.102345","volume":"32","author":"D Hwang","year":"2021","unstructured":"Hwang D, Dismuke T, Tikunov A, Rosen EP, Kagel JR, Ramsey JD, et al. Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity. Nanomedicine. 2021;32:102345.","journal-title":"Nanomedicine"},{"issue":"1","key":"1018_CR66","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jconrel.2011.04.010","volume":"153","author":"R Luxenhofer","year":"2011","unstructured":"Luxenhofer R, Sahay G, Schulz A, Alakhova D, Bronich TK, Jordan R, et al. Structure-property relationship in cytotoxicity and cell uptake of poly(2-oxazoline) amphiphiles. J Control Release. 2011;153(1):73\u201382.","journal-title":"J Control Release"},{"issue":"13","key":"1018_CR67","doi-asserted-by":"publisher","first-page":"e2206737","DOI":"10.1002\/advs.202206737","volume":"10","author":"M Yin","year":"2023","unstructured":"Yin M, Dong J, Sun C, Liu X, Liu Z, Liu L, et al. Raddeanin A Enhances Mitochondrial DNA-cGAS\/STING Axis-Mediated Antitumor Immunity by Targeting Transactive Responsive DNA-Binding Protein 43. Adv Sci (Weinh). 2023;10(13):e2206737.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"1018_CR68","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1038\/s41467-024-48327-9","volume":"15","author":"TS Johnson","year":"2024","unstructured":"Johnson TS, Sudha P, Liu E, Becker N, Robertson S, Blaney P, et al. 1q amplification and PHF19 expressing high-risk cells are associated with relapsed\/refractory multiple myeloma. Nat Commun. 2024;15(1):4144.","journal-title":"Nat Commun"},{"issue":"20","key":"1018_CR69","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1182\/blood.2024024590","volume":"144","author":"M John","year":"2024","unstructured":"John M, Helal M, Duell J, Mattavelli G, Stanojkovska E, Afrin N, et al. Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma. Blood. 2024;144(20):2121\u201335.","journal-title":"Blood"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-01018-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-01018-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-01018-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:03:47Z","timestamp":1791572627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-01018-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1018"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-01018-7","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"14 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the local Ethics Committee of the University of W\u00fcrzburg (224\/20-am). All patients signed written informed consent forms in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All co-authors have approved the manuscript and agree with its submission to Biomarker Research.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R.L. is listed as co-inventor pertinent to materials used in the manuscript. R.L. is co-founder of DelAqua Pharmaceuticals Inc., which is intent on commercialization of poly(2-oxazoline) nanomedicines. All other authors declare no competing financial interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"135"}}